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Abstract
Neuropeptides are small protein-like signaling molecules with diverse roles in regulating neural functions such as sleep/
wake cycles, pain modulation, synaptic plasticity, and learning and memory. Numerous drugs designed to target
neuropeptides, their receptors, or relevant pathways have been developed in the past few decades. Hence, the discovery
and characterization of new neuropeptides and their functions have received considerable attention from scientific
research. Computational bioinformatics coupled with functional assays are powerful tools to address the difficulties in
discovering new bioactive peptides. In this study, a new bioinformatic strategy was designed to screen full length human
and mouse cDNA databases to search for novel peptides. One was discovered and named peptide Lv because of its ability
to enhance L-type voltage-gated calcium channel (L-VGCC) currents in retinal photoreceptors. Using matrix-assisted laser
desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), peptide Lv was detected in the culture media,
which indicated that it was secreted from 661W cells transfected with the gene. In vitro treatments with either glutathione
S-transferase (GST) fusion peptide Lv or synthesized peptide Lv enhanced L-VGCC channel activities in cone photoreceptors.
At the molecular level, peptide Lv stimulated cAMP production, enhanced phosphorylation of extracellular signal-regulated
kinase (ERK), and increased the protein expression of L-VGCCa1 subunits in cone photoreceptors. Therefore, the biological
activities of peptide Lv may be very important in the modulation of L-VGCC dependent neural plasticity.
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Introduction
Neuropeptides act like peptidic hormones or neurotransmitters
and play diverse roles in regulating neural functions [1], [2], [3],
[4]. Numerous drugs designed to target neuropeptides, their
receptors, or relevant pathways have been developed in the past
few decades [1], and the discovery and characterization of new
neuropeptides and their functions have received considerable
attention from both scientific research and clinical practice.
Identification of new bioactive peptides is challenging because
they are short in length, have limited information on their core
sequences and structures, and have highly diverse physiological
functions. Historically, biochemical purification coupled with
functional assays was the major method for discovering neuro-
peptides. However, advancements in computational bioinfor-
matics with growing DNA and protein databases have successfully
predicted secretory peptides in recent years [5], [6], [7]. Small
peptide hormones and neurotransmitters share some common
features, including a signal peptide sequence and pre-hormone
cleavage sites [8]. The Hidden Markov model, a bioinformatic
model used for domain predictions, has proven successful in
identifying novel peptides from the human proteome. It includes
the common features of small peptides mentioned above [9].
Therefore, bioinformatic approaches coupled with activity assays
have become a powerful tool to address the difficulties in
discovering new bioactive neuropeptides.
Our goal was to develop a new bioinformatic strategy for
discovery of novel bioactive peptides that might have important
roles in regulating neural excitability and plasticity. In this study,
we present a newly designed bioinformatic strategy modified from
the Hidden Markov model to screen full length cDNA databases in
search of novel secretory peptides. Our improved screening
protocol included more propeptide convertase cutting motifs, as
well as transmembrane domains in propeptide candidates, since
several peptides or secretory proteins are derived from precursors
with transmembrane domains [10], [11], [12]. Concurrently,
several activity assays were employed to examine the bioactivities
of the candidate peptide, including biochemical and electrophys-
iological assays.
Here, we focused on a novel peptide that we discovered
through the screening process described above. The amino acid
sequence of this novel peptide is highly conserved across species
and is widely expressed in various tissues and the central nervous
system, including the retinal photoreceptor layer, hippocampus,
olfactory bulb, and cerebellum. Using patch-clamp electrophys-
iological recordings, we found that this peptide enhanced L-type
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voltage-gated calcium channel (L-VGCC) currents in photore-
ceptors through increasing the mRNA and protein expression of
both L-VGCCa1C and a1D subunits, the major L-VGCC pore
forming subunits present in neurons and retina photoreceptors
[13]. Hence, we named this peptide as ‘‘peptide Lv’’. In various
cell types, L-VGCCs mediate voltage-dependent, depolarization-
induced Ca2+ influx and regulate diverse biological processes
such as contraction, secretion, differentiation, synaptic plasticity,
and gene expression [14], [15], [16], [17]. The L-VGCCs are
also essential in gating prolonged neurotransmitter release from
retina photoreceptors [18]. The L-VGCC activity can be
modulated by neurotransmitters, hormones, cytokines, as well
as intracellular signal transduction pathways [16], [19]. To that
end, peptide Lv was able to stimulate cAMP production and
activate mitogen-activated protein kinase (MAPK) signaling.
Hence, we may have discovered a new bioactive peptide that
can potentially modulate a variety of functions associated with L-
VGCCs.
Experimental Procedure
In Silico Screening of Novel Peptides from Human and
Mouse Full Length cDNA Database
The purpose of the computational screening was to discover the
candidate genes encoding novel bioactive peptides that have never
been characterized before. Human (21,243 genes) and mouse
(21,076 genes) full length cDNAs were downloaded from the
database [20], [21]. The screening strategy (Fig. 1) found no new
DNA sequence. Several features in the biological production of
peptide hormones were taken into consideration in our screening
process for candidate genes. Amino acid sequences were screened
using several algorithms, including SignalP 3.0 (set as default, D-
cut off at 0.45) for the prediction of signal peptides, the Dense
Alignment Surface (DAS) method (.2.0 cut off) to identify
transmembrane domains, and Expasy NetNGlyc 1.0 to predict N-
glycosylation sites (potential threshold set as .0.6). Sequence
comparisons among humans, rats, and mice (.50% homology)
were carried out using the NCBI database and UCSC genomic
browser. A detailed list of genes from each screening step is in
Data S1. The proprotein cleavage cutting motifs mainly included
dibasic amino acid sequences such as GKK/GRR, RKX, RRX,
KR, RXKR, KXRR, and RFGK. We selected 5 candidate genes
based on their distribution in the Expressed Sequence Tag (EST)
database as potential ‘‘proproteins’’ and examined their bioactiv-
ities. Here, we present one of the candidate genes that encoded
‘‘peptide Lv’’.
Cloning of Mouse Peptide Lv Full Length cDNA
To clone the candidate cDNA, a commercially available kit
(Qiagen, Valencia, CA) was used to isolate total RNA from an
adult male C57BL6 mouse cerebral cortex. 1 mg total RNA was
subjected to reverse transcription for first strand synthesis
(Invitrogen, Carlsbad, CA). The full length mouse E130203
B14Rik cDNA (NM_178791.4) was amplified by PCR (Invitrogen;
sense primer: 59-GAATTCATGCGGCTCCTAGCGCTGG CG
GCGG-39; antisense primer: 59-CTCGAGCTACAGCTGGT
TCTCCTCGAAGAGGA-39). The PCR fragment was purified
and inserted into a pGEM T-easy vector (Promega, Madison, WI)
for sequencing. For expression in mammalian cells (the 661W cell-
line, described below), the full length cDNA was inserted into a
pCAGIG vector.
Cell Culture and Transfection
Fertilized eggs (Gallus gallus) were obtained from the Department
of Poultry Sciences, Texas A&M University (College Station, TX).
Dissociated chicken cone photoreceptors from embryonic day 10
(E10) or E16 were cultured for 2 days as described previously in
the presence of 20 ng/ml ciliary neurotrophic factor (CNTF,
R&D Systems, Minneapolis, MN), 10% heat-inactivated horse
serum (Lonza, Basel, Switzerland), and 100 u/ml penicillin/
100 mg/ml streptomycin (Lonza) [20]. Cultures prepared in the
presence of CNTF yield a highly enriched population (70,80%)
of cone photoreceptors [21], [22], [23]. The immortalized mouse
cone photoreceptor cell line, 661W, was obtained from Dr. M. R.
Al-Ubaidi (University of Oklahoma College of Medicine, Okla-
homa City, OK) [24]. The 661W cells were cultured in Dulbecco’s
modified Eagle medium (Lonza) containing 10% fetal bovine
serum (Thermo Scientific, Rockford, IL) and 100 u/ml penicillin/
100 mg/ml streptomycin (5% CO2, 37uC). Transfections were
performed using lipofectamine 2000 transfection reagent (Invitro-
gen). The culture media were replaced 12 hr after transfection.
The new media were collected 48 hr after transfections.
High-performance Liquid Chromatography (HPLC) and
Mass Spectrometry (MS)
Media collected from cultured murine 661W photoreceptor
cells were filtered and concentrated through Amicon Ultracel-10
and Ultracel-3 centrifugal filters, respectively (Millipore, Billerica,
MA). After filtration, concentrated samples were loaded onto a
Dionex HPLC system (Acclaim C18 column, Ultimate 3000
variable wavelength detector; Dionex, Bannockburn, IL), and a
linear gradient (10%–80% acetonitrile [ACN]/H2O with 0.1%
trifluoroacetic acid [TFA]; 30 mins; 1 ml/min) was used for final
elution. The HPLC elutate (fractions from retention time 15–
25 min) was concentrated (SpeedVac, Thermo Fisher Scientific,
Waltham, MA) for further determination of the molecular weights
by MS. MALDI-TOF MS was performed by an ABI Voyager-DE
STR (Department of Chemistry, Texas A&M University, College
Station, TX). Samples were ionized by sinapic acid (1:1 ratio).
Figure 1. A flow chart illustration of the in silico computational
screening strategy and procedure. Human and mouse full length
protein databases were subjected to five step separation computer
algorithms including N-terminal signal peptide sequence (secretion
marker), propeptide convertase targeting motif, transmembrane
domain, potential glycosylation modification, and sequence homology
across species. Potential candidates were ranked according to the score
assigned from each step (Data S1).
doi:10.1371/journal.pone.0043091.g001
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In Situ Hybridization
Whole brains and eyes from five adult male C57BL/6 mice
were collected after perfusion with 4% paraformaldehyde in PBS
and post-fixed with paraformaldehyde for another 4 hr, followed
by suspension in 30% sucrose/PBS overnight. Samples were then
mounted in optimum cutting temperature (O.C.T.) embedding
compound (Tissue-Tek; Sakura Finetek, Torrance, CA) and
12 mm saggital sections were cut (Leica Microsystems, Buffalo
Grove, IL). The biotin labeled probe was the in vitro transcripted
antisense RNA of murine peptide Lv (Roche, Indianapolis, IN)
including a 300 bp region from the ATG start code in exon 1 to
the XhoI cutting site in exon 2. Final images were obtained by
alkaline phosphatase conjugated to streptavidin and substrate
BCIP (5-bromo-4-chloro-39-indolyphosphate p-toluidine salt)/
NBT (nitro-blue tetrazolium chloride; Roche). All procedures
involving mice were approved by the Institutional Animal Care
and Use Committee (IACUC) of Texas A&M University
consistent with approved protocols described in the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals (National Institutes of Health Publication No. 85–23,
revised 1996). Mice were housed under standard temperature and
humidity controlled conditions with 12:12 hr LD cycles and fed
standard laboratory chow and water ad libitum.
Immunoblotting, Quantitative (Q)-PCR, and cAMP
Immunoassay
Cone photoreceptors from E10 embryos were cultured for
2 days. The cells were treated with murine GST-peptide Lv at a
final concentration of 800 ng/ml or synthesized murine peptide
Lv at a final concentration of 500 ng/ml for 4 hrs. Murine GST-
peptide II or PBS served as control. Peptide II was derived from
same encoding gene as peptide Lv as indicated in Figure 2 (orange
color). The sequence of peptide II was located adjacent to the
coding region of peptide Lv. Since peptide II and peptide Lv were
from the same encoding gene, we selected the peptide II as an
internal control to ensure that the bio-activity of peptide Lv was
sequence specific. Treated or control cells were washed, lysates
were obtained by suspension of cells in RIPA lysis buffer, and
proteins were denatured by mixing with 2X Lamelli sample buffer
for 5 min at 95uC. Primary antibodies for pan L-VGCCa1
(Chemicon/Millipore, Temecula, CA), ERK1 (sc-94, Santa Cruz
Biochemicals, Santa Cruz, CA), pAKT308 (Cell Signaling Tech-
nology, Danvers, MA), and pERK (M9692, Sigma, St. Louis, MO)
were incubated overnight at 4uC. Blots were visualized by
appropriate secondary antibodies and an ECL detection system
(Pierce, Rockford, IL). For some experiments, pertussis toxin
(PTX; Calbiochem/EMD, San Diego, CA) was added to a final
concentration of 0.5 mg/ml. For Q-PCR, peptide Lv treated or
control cells were harvested, and total RNA was isolated as
described above. One step RT-PCR amplification (Applied
Biosystems, Foster City, CA) was used for detection of L-
VGCCa1D and b-actin mRNA expression. Primers and probes
for L-VGCCa1D and b-actin mRNA were listed previously [20].
For VGCCa1C, the primers and probe sequences are forward
primer: 59-TCTCGCATCTCA ATCACCTTCTTC-39, reverse
primer: 59-GGCTCAGGAGCTTCACAAGAC-39, and MGB-
Probe: 59-ATCACGCGGAAGAGTC-39. For mouse GAPDH,
the forward primer was 59-CATTGTGGAAGGGCTCAT-
GACCA-39, and reverse primer was 59-TGGGATGACCTT
GCCCACAGCCTTG-39. Cyclic AMP levels were detected by a
commercially available kit (Arbor Assays, Ann Arbor, MI). The
final cAMP concentration was normalized to protein concentra-
tion (Bradford method; Bio-rad, Hercules, CA).
GST Fusion Protein Purification and Peptide Synthesis
The coding region of murine peptide Lv and murine peptide II
(control peptide) were amplified by high fidelity PCR (Invitrogen;
sense primers: 59-ATAGAATTCGACAGCTTGCTGGCCG
TGCGC-39 [peptide Lv], 59-ATAGAATTCGGGGTGCTG
TACAGGCTGTCTG-39 [peptide II]; antisense primers: 59-
ATACTCGAGACGCTCCTCGAGCTGGCGTAG-39 [peptide
Lv], 59- ATACTCGAGCTCAAATGATGAAATCTTCGCC-39
[peptide II]). PCR fragments were verified by DNA sequencing
and inserted into pGEX-4T1 expression vectors (EcoRI/NotI).
The plasmids were transformed into BL21 E. coli. The expression
of fusion proteins was induced by 0.5 mM isopropyl b-D-1-
thiogalactopyranoside (IPTG) and confirmed by SDS-PAGE. The
GST fusion proteins were purified with a commercially available
kit (Pierce, Rockford, IL). Briefly, E. coli cells were collected and
disrupted by sonication. The supernatants were loaded onto GSH-
sepharose 4B columns. The flow through and final elution from
the beads were collected for SDS-PAGE. The final GST-peptide
Lv product was dialyzed against PBS. Synthesized peptide Lv
(over 90% pure) was purchased from Genscript (Piscataway, NJ).
Immunoprecipitation (IP)
Ten retinas from chicken embryos (E12) were collected and
lysed in 4 ml RIPA buffer containing a protease inhibitor cocktail.
The cell lysate was divided into two parts (2 ml each) and
incubated with either pre-bleed rabbit serum (1/500 dilution) or
peptide Lv specific polyclonal antibody (1/500 dilution) for 3 hr at
4uC. The rabbit polyclonal antibody was custom-made by
Biomatik (Ontario, Canada) against synthesized peptide Lv and
purified by a protein A affinity column. 25 ml immobilized protein
A resin (G biosciences, St. Louis, MO) were prewashed by PBS
and incubated with the cell lysates for 3,4 hr at 4uC. The resins
were washed three times with 0.05% Triton X-100 in PBS and
twice with PBS, then boiled with 25 ml SDS-PAGE sample buffer
at 95uC for 10 min. The supernatants were loaded onto 18%
SDS-PAGE gels and transferred to 0.22 mm nitrocellulose
membranes (GE Healthcare life sciences, Piscataway, NJ). The
membranes were probed by anti-peptide Lv antibody.
Patch-Clamp Electrophysiology
Whole-cell voltage-clamp recordings of L-VGCCs were carried
out as described previously [20]. The external solution contained
the following (in mM): NaCl 110, BaCl2 10, MgCl2 0.4, KCl 5.3,
tetraethylammonium chloride 20, HEPES 10, and glucose 5.6,
pH 7.4 adjusted with NaOH. The pipette solution was (in mM):
Cs acetate 135, CsCl 10, MgCl2 2, CaCl2 0.1, EGTA 1.1, and
HEPES 10, pH 7.4 adjusted with CsOH. Recordings were made
from E10+2 (E12) or E16+2 (E18) cone photoreceptors charac-
terized morphologically as cells with elongated cell bodies with one
or more oil droplets. Cells were recorded using a ramp command
from 280 to 60 mV in 500 ms, and a 200 ms step command with
holding potential at 265 mV and steps from 250 to 40 mV at
10 mV increments. The current density (Idensity) was obtained by
dividing the current amplitude by the membrane capacitance.
Each group contained 9–18 cells. The conductance-membrane
potential curves were analyzed using the Boltzmann equation,
‘‘G/Gmax = 1/(1+exp[Vmid-V/Ka])’’. G: conductance, V:
membrane voltage, Vmid: the membrane potential that elicits
half maximal activation (current), Ka: the activation slope factor.
Toward the end of each recording, nitrendipine (5 mM), a L-
VGCC blocker, was perfused through the extracellular solution for
5 min, and the final ramp-command was recorded to ensure that
each recording was the L-VGCC current.
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Statistics
All data are presented as mean 6 standard error of mean
(s.e.m.). The Student’s t test was used for statistical analysis to
compare the control and treated groups. One-way ANOVA with
Tukey post hoc test was used for comparing multiple groups.
Throughout, *p,0.05 was regarded as significant.
Results
Computational Screening of Peptide Lv from the cDNA
Database
We designed a new computational genomic screening strategy
(Fig. 1) based on the Hidden Markov model to identify new
Figure 2. Sequence alignment of propeptide Lv among different species. Mouse, rat, human, and chicken peptide Lv proprotein were over
80% homologous. The sequence contained a signal peptide sequence (green), proprotein convertase cutting motifs (red), the main peptide Lv
coding region (blue), and a transmembrane domain (purple). Peptide II (control for the electrophysiological studies) is highlighted in orange. Highly
conserved identical sequences are denoted by (*), conserved substitution by (:), and semiconserved substitution by (.).
doi:10.1371/journal.pone.0043091.g002
Identification of a Novel Neuropeptide, Peptide Lv
PLOS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e43091
peptide hormones. First, human and mouse full length cDNA
databases [25], [26] were used as our screening source, since these
cDNAs encode proteins with longer N-terminal domains that were
ideal for our purposes. Second, more propeptide convertase
cutting motifs including GKK/GRR, RKX, RRX, KR, RXKR,
KXRR, and RFGK were included in the screening procedure.
Third, some potential propeptides with unknown transmembrane
domains were included as candidates, since several bioactive
peptides or secretory proteins are derived from precursors with
transmembrane domains, such as teneurin C-terminal-associated
peptides [10], semaphoring [11], and zona proteins [12]. Hence, it
is possible that propeptide candidates may contain transmembrane
domains beyond the peptide’s coding region, and a peptide can be
proteolytically released from a transmembrane containing pro-
protein. Fourth, candidates were screened for potential glycosyl-
ation modification sites through specific algorithms [27], and those
sequences that undergo heavy glycosylation were eliminated. In
order to specifically identify secretory peptides/proteins from the
databases, several bioinformatic algorithms were developed for the
identification of N-terminal signal peptides [28]. Moreover,
secretory protein databases from several species are available
[29]. Based on our improved screening protocol, the majority of
peptide candidate genes that were identified in our screening
belonged to several families of well-studied peptide hormones or
small proteins.
We focused on poorly annotated candidates to decode novel
bioactive peptide products with uncharacterized physiological
functions. We also examined the expressed sequence tags (EST) of
these candidates and chose those that were potentially expressed in
neurons. Lastly, we chose candidates whose amino acid sequences
were highly conserved among species (see Data S1 for lists of
candidate sequences). Here, we report the properties of the mouse
E130203B14Rik gene product, which encodes a hypothetical
protein with 319 amino acids that contains an N-terminal signal
peptide sequence, a main peptide coding region, and a
transmembrane domain predicted in the C-terminal region. The
main peptide coding region from the mouse E130203B14Rik gene
contains 49 amino acids, and its sequence was conserved among
human, mouse, rat, and chicken (Fig. 2). We named this small
protein ‘‘peptide Lv’’ based on its physiological activities described
below.
Peptide Lv mRNA was Widely Expressed in Mice
We next examined the distribution of peptide Lv mRNA in
various organs, several brain regions, and the retina using RT-
PCR and in situ hybridization (Fig. 3). The mRNA of peptide Lv
was detected in the liver, lung, spleen, cerebral cortex (cortex),
cerebellum, olfactory bulb, hippocampus, eyes, and intestine, with
relatively higher levels in the spleen, cerebellum, olfactory bulb,
and hippocampus (Fig. 3A). In various brain areas, peptide Lv
mRNA was present in the cerebellum (C; Fig. 3B-a, b, c) and
located mostly in the Purkinje (P) and granule (G) cell layers. In the
olfactory bulb (OB; Fig. 3B-a, d), the mRNA of peptide Lv was
detected in the glomerular layer (GLM), and mitral (M) and
granule (G) cell layers. In the cerebral cortex (CC; Fig. 3B-a, e),
peptide Lv mRNA was widely expressed. In the hippocampus (H;
Fig. 3B-a, f), peptide Lv mRNA was present in the CA1-CA3
pyramidal cell layer and the dentate gyrus (DG) granule cell layer.
Figure 3. Expression of peptide Lv mRNA in mouse tissues. (A) Gene expression of peptide Lv in various mouse tissues was determined by RT-
PCR. The mRNA of peptide Lv was detected in the liver, lung, spleen, intestine, eyes, cerebral cortex (cortex), cerebellum, olfactory bulb, and
hippocampus, with relatively higher expression levels in the spleen, cerebellum, olfactory bulb, and hippocampus. (B) The mRNA expression of
peptide Lv in the mouse brain and retina was detected by in situ hybridization. Adult mouse brain sagittal sections and retina sections were cut at
12 mm thickness and processed. The sense probe served as the negative control (a’). Propeptide Lv mRNA was strongly expressed in the cerebellum
(C), olfactory bulb (OB), cerebral cortex (CC), and hippocampus (H). (b and c): cerebellum; P, Purkinje cell layer; G, granule cell layer; W, white matter.
(d): olfactory bulb; GLM, glomerular layer; M, mitral cell layer; G, granule cells. (e): cerebral cortex. (f) hippocampus; CA, cornu ammonis; DG, dentate
gyrus. (g) In the mouse retina, the expression of peptide Lv was detected in the outer nuclear layer (ONL), inner nuclear layer (INL), and ganglion cell
layer (GCL). The scale bars represent 1.0 mm (a and a’), 0.1 mm (b, c, d, e, f), and 0.02 mm (g).
doi:10.1371/journal.pone.0043091.g003
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In the mouse retina (Fig. 3B-g), the outer nuclear layer (ONL),
where the cell bodies of photoreceptors are located, had the
highest expression of peptide Lv mRNA, while both inner nuclear
layer (INL) and ganglion cell layer (GCL) also contained peptide
Lv mRNA. Since retina photoreceptors had a relatively high
density of peptide Lv mRNA, we used photoreceptors for the
following bioactivity assays to investigate the functional properties
of peptide Lv.
Peptide Lv was Secreted in vitro
Since one of our bioinformatic screening criteria was to find
secretory bioactive peptides, we next examined whether peptide
Lv was secreted from cultured cells. We transfected 661w cells, a
mouse cone photoreceptor cell line, with mouse E130203B14Rik
gene or an empty vector (control). If peptide Lv was expressed and
secreted from transfected cells into the culture media, mass
spectrometry would be able to detect the peptide from collected
culture media. Transfection efficiency was monitored by coex-
pression of green fluorescence protein (GFP). The samples
(collected culture media) were filtered through 10 kD and 3 kD
cut off filters followed by partial purification through an HPLC
C18 column to eliminate high molecular weight proteins, residual
chemical background, and salt. The HPLC eluate was concen-
trated and analyzed by MALDI-TOF MS (Fig. 4). The predicted
molecular weight for peptide Lv from the bioinformatic assessment
was 5805.6982 D. There were five major molecular weight peaks
between 5 kD and 10 kD detected by MALDI-TOF MS: 5083.73,
5671.25, 5808.66, 8412.02, and 8586.64 m/z. Compared to the
molecular weights detected in the control sample (5071.45,
5375.00, 5491.28 and 5665.46 m/z), the specific molecular weight
at 5808.66 m/z from the transfected samples was consistent with
the predicted molecular weight for peptide Lv. Therefore, this
result demonstrates that the mouse E130203B14Rik gene
produced peptide Lv that was secreted from transfected 661w
cells (Fig. 4). Although, there was a difference in the peaks
(8586.64 m/z and 8412.02 m/z) between transfected and control
samples, it was not clear whether it was a fragment derived directly
from the transfected gene or other secretory fractions that was
affected indirectly by the transfection of our targeted gene.
We obtained a custom-made rabbit polyclonal antibody against
the synthesized peptide Lv. The antibody specifically recognized
the synthesized peptide Lv (Fig. 4B, Lane 1) without cross reaction
to nonspecific proteins (Fig. 4B Lane 2). Since we detected peptide
Lv secretion from transfected cells, we next examined whether we
could detect endogenous peptide Lv by using this antibody.
Because of limitations in the amount of sample we could load, we
were not able to detect peptide Lv from the whole cell lysate
prepared from 10 chicken retinas (Fig. 4B, lane 2). It implies a
limited or low expression or secretion of peptide Lv in the retina.
We further proceeded with the immunoprecipitation by using the
peptide Lv antibody to enrich the portion of endogenous peptide
Lv from the whole cell lysate preparation. Since the predicted
molecular weight of endogenous peptide Lv was small, we ran an
18% SDS-PAGE gel followed by Western immunoblotting with
the same peptide Lv antibody. There was a specific endogenous
peptide Lv positive band detected in this immunoprecipitation
enriched retina sample, and the molecular weight of endogenous
peptide Lv is slightly higher than the synthesized peptide Lv (Fig. 4,
Lane 4). It is possible that the higher molecular weight of the
endogenous peptide Lv was due to post-translational modification.
The strong positive bands above 10 kDa are due to the light chains
(,27 kDa) of the antibodies. This result demonstrated the
expression of endogenous peptide Lv in the retina.
Peptide Lv Stimulated cAMP Production and ERK
Phosphorylation in Chicken Cone Photoreceptors, and
PTX Blocked these Effects
Signaling by many peptide hormones or transmitters is
mediated through the G-protein coupled receptor (GPCR) family
[30]. Intracellular signaling pathways involving GPCRs vary
depending on the coupled G-proteins and the downstream
effectors [31]. However, cAMP, an intracellular second messenger,
plays a key role mediating G protein signaling response to GPCRs.
Therefore, we investigated whether the cAMP level changed when
cells were stimulated by peptide Lv, even though we have not yet
identified the specific receptor(s) for peptide Lv. We found that
treatment with commercially custom synthesized peptide Lv
increased intracellular cAMP levels after cells were treated for
15 min (Fig. 5A). Activation of cAMP signaling often stimulates
the phosphorylation of ERK (pERK), a downstream component of
the cAMP signaling pathway [32], so we next determined whether
peptide Lv might also trigger phosphorylation of ERK. Treatment
with synthesized peptide Lv for 30 min also elicited an increase of
ERK phosphorylation (Fig. 5B). While treatment with peptide Lv
for four hours elicited an increased intracellular cAMP level up to
2.7460.57 folds (Fig. 5D) and the phosphorylation of ERK up to
4.3761.09 folds (Fig. 5C, D), PTX diminished the peptide Lv
elicited increase of cAMP and ERK phosphorylation. Treatment
with PTX alone did not change cAMP levels or ERK
phosphorylation compared to the control (Fig. 5C, D). Thus,
PTX-sensitive G protein coupled receptors might be involved in
the action of peptide Lv.
Peptide Lv Enhanced L-VGCC Currents in Chicken Cone
Photoreceptors
Since cAMP and pERK have been reported to regulate L-
VGCC activity in cardiomyocytes and photoreceptors [20,33],
and we showed that peptide Lv enhanced cAMP production and
ERK phosphorylation (Fig. 5), we next investigated whether
peptide Lv might activate L-VGCC activity in chicken cone
photoreceptors. We generated a GST-fusion peptide Lv and a
GST-fusion peptide II from E. coli (Fig. 6A) for the following
electrophysiological experiments, since the GST fusion peptides
can be easily expressed and purified from E. coli, and the
recombinant peptides generated can mimic the activities of
endogenous peptides [34], [35], [36], [37]. We took advantage
of primary dissociated cell cultures of chicken photoreceptors for
the following assays, because these cells have oil droplets present at
the inner segments [22], which allow for easier identification under
the microscope for patch-clamp recordings, and the cultures can
be easily maintained in an incubator for several days. Cultured
E18 (16+2) cone photoreceptors were treated with either GST-
fusion peptide Lv, GST-fusion peptide II, or PBS (vehicle) for 4 hr
prior to patch-clamp recordings. Cells treated with GST-fusion
peptide Lv (800 ng/ml) had significantly higher L-VGCC current
densities (10.9360.70 pA/pF) compared to PBS treated cells
(8.4061.11 pA/pF; Fig. 6C, D), while treatment with GST-fusion
peptide II did not increase L-VGCC current densities (Fig. 6E, F).
Nitrendipine (5 mM), a L-VGCC blocker, abolished the L-VGCC
currents in cells treated with peptide Lv (Fig. 6 D). We further
obtained a commercially custom synthesized peptide Lv that had a
similar purity (over 90%) to our own GST-fusion peptide Lv.
There was no difference in the voltage-current relationship of L-
VGCCs between treatments with either GST-fusion or synthe-
sized peptide Lv as shown in Figs. 6C and 7D, respectively. We
also analyzed the activation kinetics from the conductance-voltage
(G–V) curve (Fig. 6G). While the membrane voltage of half of
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maximal conductance (G/Gmax at 0.5) was 1.2561.20 mV for
the control and 21.0361.17 mV for GST-peptide Lv treated
photoreceptor cells, there was no statistical difference. In the tail-
current analysis, there was no difference between GST-peptide Lv
treated and control cells in Tau (ms) as well as current-voltage
relationship (Fig. 6H). These data imply that the increase of
L-VGCC currents by GST-peptide Lv is not through changing of
channel gating kinetics in photoreceptors.
Even though treatment with commercially synthesized murine
peptide Lv for 15 or 30 min elicited changes in intracellular
signaling, mainly increases in cAMP levels and ERK phosphor-
ylation, treatment with commercially synthesized peptide Lv for 15
Figure 4. Verification of peptide Lv secretion by MALDI-TOF mass spectrometry. (A) Mouse 661w cells were transfected with the
propeptide Lv gene (mouse E130203B14Rik) expression vector or empty vector (control). Culture media were collected 48 hr after transfection,
filtered (3,10 kD), and subjected to HPLC. The final elution (linear gradient 10%–80% ACN/H2O and 0.1% TFA in all solutions, fractions from 15–
25 min retention time) was concentrated by speedvac and analyzed by MALDI-TOF MS. The arrowhead indicates the peak (5808.66 m/z) that
corresponds to the predicted molecular weight of peptide Lv (5805.6982 m/z). The 49 amino acid sequence of peptide Lv is listed at the top of this
panel. (B). A custom-made rabbit polyclonal anti-peptide Lv antibody against synthetic peptide Lv was obtained for detecting endogenous peptide
Lv in chicken retinas. A 2 ml cell lysate sample prepared from 10 chicken retinas was used for immunoprecipitation with anti-peptide Lv antibody to
concentrate (enrich) the endogenous peptide Lv in the cell lysate followed by Western immunoblotting. Lane 1 was loaded with the synthesized
peptide Lv. Lane 2 was loaded with the whole retinal cell lysate (10 ml). Lane 3 was loaded with the retinal cell lysate that was immunoprecipitated
with the pre-bleed rabbit serum, served as a negative control. Lane 4 was loaded with the retinal cell lysate immunoprecipitated with the anti-
peptide Lv antibody. *indicates the endogenous peptide Lv pulled down from the enriched cell lysate (Lane 4).
doi:10.1371/journal.pone.0043091.g004
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or 30 min did not alter L-VGCC currents (Fig. 7A). Therefore, the
enhanced L-VGCC currents by 4 hr treatment with peptide Lv
might not be en route through cAMP-dependent protein kinase A
or ERK signaling for the direct phosphorylation of L-VGCC
subunits in chicken cone photoreceptors. We found that treatment
with peptide Lv increased the protein expression of the L-
VGCCa1 subunit within 3 hr (Fig. 7B; 3.0661.04 folds increase
for 3 hr and 2.5460.83 folds increase for 4 hr). More specifically,
treatment with peptide Lv for 4 hr induced the up-regulation of
both VGCCa1C and a1D mRNA levels (Fig. 7C; 2.8360.91 and
3.8360.94 folds, respectively). While treatment with PTX
diminished the effect of peptide Lv on cAMP increase and ERK
phosphorylation, PTX did not eliminate the effect of peptide Lv
on L-VGCCs (Fig. 7D). Therefore, peptide Lv augmentation of
photoreceptor L-VGCC currents was through increased mRNA
and protein expression of the a1 subunits. While treatment with
synthesized peptide Lv (500 ng/ml) on cultured E18 (16+2)
photoreceptors caused an increase of L-VGCC current density,
peptide Lv elicited a larger increase of L-VGCC currents on
cultured E12 (E10+2) photoreceptors (Fig. 7E, F). This result
demonstrates that peptide Lv had a developmental stage-
dependent effect on L-VGCCs in photoreceptors.
Discussion
In this report, we combined bioinformatic, peptidomic,
biochemical, and electrophysiological methods to screen novel
secretory peptides that have potential biological effects on neural
physiology and function. Our in silico screening strategy included
more features that specifically targeted secretory peptide process-
ing, such as prohormone cleavage sites, minimal glycosylation,
Figure 5. Peptide Lv enhanced cAMP production and ERK phosphorylation in chicken cone photoreceptors. (A and B) Cultured chick
photoreceptors (E10+2) were treated with 500 ng/ml commercially synthesized peptide Lv or control buffer for 0, 15, 30, 60, or 120 min prior to
harvest. (A) The cAMP levels increased after 15 min treatment of peptide Lv (n = 6 for each time point). *indicates that the cAMP levels at 15 and
120 min were significantly higher than 0 min (One-way ANOVA, Tukey post hoc, *p,0.05). (B) Total ERK and pERK were detected by Western blots.
The band densities were measured, and the values were calculated as a ratio of pERK to total ERK. Relative fold difference was calculated by
comparison to the control, in which the control was set as 1 (n = 5 for each time point). *indicates that the pERK level at 0 min is significantly different
from 30, 60, and 120 min (One-way ANOVA, Tukey post hoc, *p,0.05). #indicates that pERK levels at both 30 and 60 min are significantly different
from 15 min (One-way ANOVA, Tukey post hoc, #p,0.05). (C and D) The effect of peptide Lv on pERK and cAMP is dampened by PTX. Peptide Lv
increased cAMP levels (2.7460.56) and the phosphorylation of ERK (4.3761.09) after 4 hours of treatment (D). However, PTX blocked the effects of
peptide Lv (n = 5 for each treatment). For cAMP levels, * indicates that the peptide Lv treated group is significantly higher than the control and PTX
treated groups (One-way ANOVA, Tukey post hoc, *p,0.05). For pERK levels, *indicates that the peptide Lv treated group is significantly higher than
all other groups, while #indicates that the peptide Lv+PTX group is significantly higher than the control and PTX treated groups (One-way ANOVA,
Tukey post hoc, both *and #indicate p,0.05).
doi:10.1371/journal.pone.0043091.g005
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signal peptide motifs, and sequences conserved across different
species. The purpose of this screening strategy was to provide
higher numbers of potential candidates with minimal false positive
selections. Our screening procedure was based on the protein
database derived from full length cDNA sequences from human
and mouse. As such, it is possible that some genes were not
included in these databases. Additionally, we only selected
candidate genes with encoded amino acid sequences that were
Figure 6. GST-peptide Lv increased L-VGCC currents in cone photoreceptors. GST-peptide Lv and GST-peptide II (control) were expressed
and purified from E. coli. The image of lysate (Load), column flow through (FT), and the purified proteins (Purified; over 90% purity) was shown (A). (B–
H) Cultured E18 (E16+2) cone photoreceptors were treated with PBS (control), 800 ng/ml GST-peptide II (control peptide), or 800 ng/ml GST-peptide
Lv for 4 hrs prior to recordings. Whole cell patch-clamp recordings were performed under both step and ramp commands. Representative current
traces under a step commend (B) or a ramp command (D, F) are shown. Average current-voltage (I-V) relationships were obtained from the step
command as in current density (pA/pF), and the maximum inward current densities were elicited at 0 to 10 mV of the step command (C, E). (C) The
average maximal current density obtained from GST-peptide Lv treated cells (n = 17, open circle) was significantly larger than the control (n = 9; filled
square). Toward the end of each recording, nitrendipine (5 mM), was perfused through the extracellular solution for 5 min, and the final ramp-
command was recorded. A representative current trace with nitrendipine perfusion is shown in (D). (E) There was no significant difference between
the control (n = 13) and GST-peptide II treated cells (n = 18; gray circle). (G) The conductance and voltage relationship were analyzed based on cells
recorded under the step command, and the G/Gmax and voltage relationship from the control (filled square) and GST-peptide Lv treated (open circle)
are plotted. (H) The tail-current amplitude (pA) and Tau (t; ms; the insert) from both control (filled square) and peptide Lv treated (open circle) were
analyzed. Comparisons between the control and GST-peptide Lv or GST-peptide II treated groups were made using Student’s t-test; *p,0.05.
doi:10.1371/journal.pone.0043091.g006
Figure 7. Synthesized peptide Lv increased the mRNA and protein expression of L-VGCCa1 subunit in cone photoreceptors.
Cultured E18 (E16+2) photoreceptors were treated with 500 ng/ml synthetized peptide Lv for 0 (control, filled square), 15 (gray circle), or 30 min
(triangle). Averaged current-voltage (I–V) relationships were obtained from the step command as in current density (pA/pF) and membrane voltage
(mV). (B) Treatment with peptide Lv for at least 3 hrs elicited an increase of L-VGCCa1 subunit expression. * indicates that treatment with peptide Lv
for 3 or 4 hrs is significantly different from the other groups (One-way ANOVA, Tukey post hoc, *p,0.05). (C) Treatment with peptide Lv for 4 hrs
(dark gray) significantly increased the mRNA levels of both a1C and a1D compared with the control (light gray, n = 6 for each group). * indicates the
statistical difference between the peptide Lv treated group and control (Student’s t-test; *p,0.05). (D) Compared to the treatment of peptide Lv
alone (filled circle), treatment with 0.5 mg/ml PTX did not dampen the effect of peptide Lv (triangle). (E and F) The effect of peptide Lv was
developmental age dependent. Chicken cone photoreceptors at E12 (E10+2) or E18 (16+2) were cultured and treated with peptide Lv. Peptide Lv
significantly increased current density at E12 (E12: control, 24.4960.66 pA/pF, n = 9, open square; peptide Lv treated cells, 27.2260.45 pA/pF,
n = 16, dark square. E18: control, 28.4061.11 pA/pF, n = 9, open triangle; peptide Lv, 210.9360.70 pA/pF, n = 17, dark triangle). Comparisons
between the control and peptide Lv treated groups were made using Student’s t-test; *p,0.05.
doi:10.1371/journal.pone.0043091.g007
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highly conserved across different species. This criterion could rule
out potential candidate genes that are species specific. We used
whole-cell electrophysiological recordings on single cells as an
assay method to provide a simple and quick assessment of the
bioactivity of the potential candidate peptides. The sequence of
peptide Lv is embedded in the mouse E130203B14Rik gene,
which is known as ‘‘Mus musculus 0 day neonate eyeball cDNA, a
hypothetical Immunoglobulin and major histocompatibility com-
plex domain containing protein’’ (AK053685.1). In addition to
peptide Lv, this gene could encode other bioactive molecules. The
mRNA of peptide Lv is expressed in various organs in mice, so it is
possible that its actions are not limited to the nervous system. We
found that peptide Lv mRNA was heavily distributed in the
photoreceptor layer of the retina. Consequently, we found that
peptide Lv modulated L-VGCC activities in retinal photorecep-
tors, which might reveal a potential new mechanism in the
regulation of neuronal function and physiology in the retina.
We found that exogenous peptide Lv enhanced calcium
currents, and superfusion of L-VGCC inhibitor nitrendipine
blocked the peptide Lv-augmented calcium currents, which
indicates that peptide Lv indeed enhanced the L-type VGCCs,
but not N- or P/Q type. It bears noting that the L-type VGCC is
the major calcium channel in retinal photoreceptors [38] [18],
[20]. Peptide Lv enhanced L-VGCC currents in photoreceptors
may in part be through increasing the expression of mRNA and
protein levels of the L-VGCCa1 subunits. However, since it took
at least 3 hr of peptide Lv treatment to significantly increase
mRNA and protein levels of L-VGCCa1 subunits, as well as the
L-VGCC currents, we cannot exclude the possibility that our
observation of mRNA and protein levels might be a consequence
of other posttranscriptional and posttranslational mechanisms,
which we have yet to explore. Calcium influx through the L-
VGCCs is essential for neurotransmitter release in retinal
photoreceptors, bipolar cells, and other non-spiking neurons
[18]. Treatment with peptide Lv at E12 induced a larger increase
of L-VGCC currents than at E18, indicating that peptide Lv might
have a developmental stage-dependent effect or a potential trophic
factor-like bioactivity. The L-VGCCs are also involved in synaptic
plasticity and learning and memory [39]. In the hippocampus,
long-term potentiation (LTP) is considered to be the major cellular
mechanism underlying learning and memory [40]. Inactivation of
Cav1.2 (VGCCa1C) in the hippocampus and neocortex impairs L-
VGCC dependent LTP [17]. We found that peptide Lv increased
L-VGCC current density through increasing both mRNA and
protein expression of L-VGCCa1 subunits after 4 hr of treatment.
Interestingly, we observed high expression of peptide Lv mRNA in
the mouse hippocampus. Moreover, peptide Lv elevated intracel-
lular cAMP production and phosphorylation of ERK, both of
which are critical for the induction and maintenance of LTP [41],
[42]. Hence, we postulate a potential role of peptide Lv in the
modulation of hippocampal LTP and synaptic plasticity. Since
peptide Lv is present in different organs, it will be worthwhile to
investigate additional functions of peptide Lv in the future.
The cellular signaling of many peptide hormones or transmitters
is mediated through GPCRs. Over 600 GPCRs have been
identified in humans and mice [30]. There are various intracel-
lular signaling pathways that involve GPCR signaling, depending
on which G-protein and downstream effector is coupled [31].
Although we have not yet identified the specific receptor(s) for
peptide Lv, we found that treatment with peptide Lv increased
intracellular cAMP. As a second messenger, cAMP can further
activate downstream signaling components, such as Protein kinase
A (PKA), RAS, and cAMP response element-binding protein
(CREB), which could further regulate gene expression [32], [43].
Inhibition with PTX, a Ga-protein inhibitor, dampened the effect
of peptide Lv on cAMP production and ERK phosphorylation.
Interestingly, treatment with PTX did not have a significant effect
on the increase of L-VGCCs by peptide Lv. Treatment with
peptide Lv increased cAMP production and pERK within 15 to
30 min, but it took at least 3 hours to increase the mRNA and
protein expression of L-VGCCs. In cardiomyocytes, epinephrine
enhances L-VGCCs through cAMP-PKA signaling that further
phosphorylate L-VGCCs [33], [44], but this pathway might not be
how peptide Lv increased L-VGCCs in photoreceptors. Hence, it
is possible that peptide Lv may activate different signaling
pathways and cellular effects concurrently, and its actions might
be cell-type specific, which will require future investigation.
In summary, we developed a new bioinformatics screening
strategy, and in combination with various assay methods, we
identified a novel bioactive peptide, peptide Lv. The action of
peptide Lv in enhancing L-VGCCs, as well as increasing
intracellular cAMP and activating ERK, indicates that peptide
Lv may be important in modulating neuronal function. Identifi-
cation of the specific receptor(s), signaling pathways, and other
cellular activities of peptide Lv will be important future directions
to investigate.
Supporting Information
Data S1 The Excel file contains the lists of genes in each
screening step. Sheets 1 and 2 list the human (3550 genes; sheet
1) and mouse (3164 genes; sheet 2) genes that contain potential N-
terminal signal peptide sequences and secretory signals. Unchar-
acterized proteins (154 from both human and mouse) are listed on
sheet 3, which were subjected to screening for proprotein cleavase
cutting sites, transmembrane domain, glycosylation, and homol-
ogy. Candidate sequences that did not have at least 50%
homology among humans, rats, and mice were eliminated, which
left 80 potential genes listed on sheet 4. Among these 80 candidate
genes, some were further eliminated if they contained multiple
transmembrane domains or signal transmembrane domains but
lacked proprotein cleavase cutting motifs. The final candidate
genes are listed in sheet 5.
(XLSX)
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